reports
EQS-News: Formycon reports audited annual results for the financial ye...
EQS-News: Formycon AG / Key word(s): Annual Report/Forecast Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance 25.04.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press release // April 25, 2024 Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance Preliminary results 2023 confirmed Group revenue increases by 83% compared to the previous year to a total of € ...
EQS-News: Formycon veröffentlicht testierten Jahresabschluss für das G...
EQS-News: Formycon AG / Schlagwort(e): Jahresbericht/Prognose Formycon veröffentlicht testierten Jahresabschluss für das Geschäftsjahr 2023 – Rückblick auf ein erfolgreiches operatives Jahr und übertroffene Prognose 25.04.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pressemitteilung // 25. April 2024 Formycon veröffentlicht testierten Jahresabschluss für das Geschäftsjahr 2023 – Rückblick auf ein erfolgreiches operatives Jahr und übertroffene Prognose Vorläufige Zahlen für 2023 final bestätigt Konzernumsatz steigt i...
Coherus Announces Presentation at the 2024 American Society of Clinica...
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 to June 4, 2024, at McCormick Place in Chicago. Presentation Details Abstract: 2664Title: Preliminary Results of a Phase 1, First-in-human, Dose Escalation Study of the Anti-CCR8 Cytolytic Anti...
Formycon Ag: 1 director
A director at Formycon Ag bought 2,500 shares at 38.978EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
EQS-News: Formycon invites to the conference call on the results of th...
EQS-News: Formycon AG / Key word(s): Conference/Annual Results Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024 22.04.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // April 22, 2024 Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024 Munich - Formycon AG (FWB: F...
EQS-News: Formycon lädt zur Telefonkonferenz zu den Ergebnissen des Ge...
EQS-News: Formycon AG / Schlagwort(e): Konferenz/Jahresergebnis Formycon lädt zur Telefonkonferenz zu den Ergebnissen des Geschäftsjahres 2023 ein und gibt Teilnahme an internationalen Investorenkonferenzen im 2. Quartal 2024 bekannt 22.04.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pressemitteilung // 22. April 2024 Formycon lädt zur Telefonkonferenz zu den Ergebnissen des Geschäftsjahres 2023 ein und gibt Teilnahme an internationalen Investorenkonferenzen im 2. Quartal 2024 bekannt München – Die Formycon AG (F...
EQS-News: Überzeugende Gesamtbilanz – Formycon berichtet vorläufige Za...
EQS-News: Formycon AG / Schlagwort(e): Vorläufiges Ergebnis/Prognose Überzeugende Gesamtbilanz – Formycon berichtet vorläufige Zahlen für das Geschäftsjahr 2023 und übertrifft Prognose 12.04.2024 / 22:15 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pressemitteilung // 12. April 2024 Überzeugende Gesamtbilanz – Formycon berichtet vorläufige Zahlen für das Geschäftsjahr 2023 und übertrifft Prognose Konzernumsatz steigt im Vergleich zum Vorjahr um ca. 83 % auf insgesamt 77,7 Mio. € Positives Konzern-EBITDA in Höhe von rund 1,5...
EQS-News: Convincing overall performance - Formycon reports preliminar...
EQS-News: Formycon AG / Key word(s): Preliminary Results/Forecast Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast 12.04.2024 / 22:15 CET/CEST The issuer is solely responsible for the content of this announcement. Press release // 12 April 2024 Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast Group revenue increase by 83% compared to the previous year to a total of € 77.7 million Positive Group EBITDA of around € 1.5 million a...
EQS-News: Formycon gibt Markteinführung von FYB201 (Ranibizumab) in Ka...
EQS-News: Formycon AG / Schlagwort(e): Markteinführung Formycon gibt Markteinführung von FYB201 (Ranibizumab) in Kanada (RanoptoTM) und der Schweiz (Ranivisio®) bekannt 11.04.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pressemitteilung // 11. April 2024 Formycon gibt Markteinführung von FYB201 (Ranibizumab) in Kanada (RanoptoTM) und der Schweiz (Ranivisio®) bekannt Kommerzieller Launch erschließt weitere wichtige Märkte in Europa und Nordamerika – FYB201 ist damit in 17 Ländern weltweit verfügbar Lucentis®-Bio...
EQS-News: Formycon announces commercial launch of FYB201 (Ranibizumab)...
EQS-News: Formycon AG / Key word(s): Market Launch Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®) 11.04.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press release // April 11, 2024 Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®) Commercial launch opens up additional key markets in Europe and North America, making FYB201 available in a total of 17 countries worldwide Lucentis® biosimilar FY...
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Anti...
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting – In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion –– Mechanism may enhance antitumor responses with immunotherapy –– First novel immuno-oncology product candidate discovered and developed by Coherus –– The CHS-1000 IND submission is planned for Q2 2024 – REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioScienc...
EQS-News: Formycon and Fresenius Kabi reach settlement agreement for u...
EQS-News: Formycon AG / Key word(s): Agreement Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada 18.03.2024 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. Press release // March 18, 2024 Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada Munich, Germany – Formycon AG (FSE: FYB) and its commercialization partner Fresenius Kabi today announced the signing of a settlement agreement with John...
EQS-News: Formycon und Fresenius Kabi erzielen Settlement-Vereinbarung...
EQS-News: Formycon AG / Schlagwort(e): Vereinbarung Formycon und Fresenius Kabi erzielen Settlement-Vereinbarung für Ustekinumab Biosimilar-Kandidaten FYB202 in Europa und Kanada 18.03.2024 / 10:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pressemitteilung // 18. März 2024 Formycon und Fresenius Kabi erzielen Settlement-Vereinbarung für Ustekinumab Biosimilar-Kandidaten FYB202 in Europa und Kanada München – Die Formycon AG (FWB: FYB) und ihr Kommerzialisierungspartner Fresenius Kabi gaben heute den Abschluss einer Settlem...
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial R...
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update – Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI® net sales of $52.4 million in the fourth quarter and $125.4 million in FY 2023 – – LOQTORZI™ and UDENYCA ONBODY™ successfully launched in Q1 2024 – – Reduction of work force of 30% for 2024 initiated on March 7, 2024 – – Conference call today at 5:00 p.m. Eastern Time – RED...
EQS-News: FYB201/Ranibizumab nimmt durch Zulassungen und Markteinführu...
EQS-News: Formycon AG / Schlagwort(e): Zulassungsgenehmigung/Markteinführung FYB201/Ranibizumab nimmt durch Zulassungen und Markteinführungen in MENA-Region weiter Fahrt auf 11.03.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pressemitteilung // 11. März 2024 FYB201/Ranibizumab nimmt durch Zulassungen und Markteinführungen in MENA-Region weiter Fahrt auf Kommerzialisierungspartner MS Pharma gewinnt staatlichen Tender für Ranibizumab in Saudi-Arabien Vermarktungsstart von FYB201/Ravegza® für zweites Quartal 2024 vo...
EQS-News: FYB201/Ranibizumab keeps gaining momentum with approvals and...
EQS-News: Formycon AG / Key word(s): Regulatory Approval/Market Launch FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region 11.03.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press release // March 11, 2024 FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region Commercialization partner MS Pharma wins government tender for Ranibizumab in Saudi Arabia Commercial launch of FYB201/Ravegza® planned for second quarter of 2024 Further launches planned thr...
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results ...
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024. Starting at 5:00 pm ET on March 13, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A replay of the webcast will be available on following the conclusion of the l...
Coherus Completes Divestiture of Ophthalmology Franchise
Coherus Completes Divestiture of Ophthalmology Franchise – Upfront cash payment of $170 million strengthens capital structure – – Transaction solidifies Coherus’ strategic focus in oncology – REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ: CHRS) today announced the completion of the previously announced divestiture of its CIMERLI® (ranibizumab-eqrn) ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC, to Sandoz, Inc. for upfront all-cash consideration of $170 million. This divestiture included Coherus’ CIMERLI...
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences Announces New Employment Inducement Grants REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 170,000 shares of the common stock of the Company to three newly hired employees with a per share exercise price of $2.59, the closing trading price on the grant date. One Executive Vice President level executive was granted an option to purchase 15...
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprieta...
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv – Innovative design enables five-minute pegfilgrastim-cbqv delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving UDENYCA® – REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) today announced the launch of UDENYCA ONBODY™, the company's on-body injector (OBI) presentation of UDENYCA® (pegfilgrastim-cbqv), is successfully und...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.